Wbafc stop it. You are spreading rubbish. As per philip the performance will be as per guided as they would have communicated pre Xmas otherwise. They HAVE to do that as per the listing rules. You may not like that DA does not rns when he takes a dump but for stuff like actual performance versus publicly communicated guidance they would 100% have to have updated the market pre year end if it would differ to an extent that it would have had an impact (positive or negative) on the SP.
The very fact they confirm they are using our instruments is actually huge news for me. Tata may not use our covid tests but once you have an installed base of machines you can then sell the full suite of diagnostics products for that installed base. If there is one market you would want that installed base in its India. Huge point of care opportunity. Probably the biggest.
IMO this is more important than any temporary sales kicker from kicker. The installed base will give future post covid recurring revenues.
The below gives details…. As you can see, the CHECK XF analyser solution is more for POC testing and is extraction free. So targeting airports, mobile testing etc. The CHECK RT PCR is for existing labs with testing machines.
Tata MD COVID Express RT PCR solution consists of:
Tata MD CHECK XF, a 3-Gene RT-PCR kit that is RNA extraction free and uses fast amplification protocol combined with a portable and fast qPCR analyzer. The solution has a processing time of just one hour. And can process 30 samples per batch per machine. The kit is approved by ICMR with 95%+ sensitivity and 100% specificity.
Tata MD CHECK RT-PCR Fast 3 Gene is a 3-Gene RT-PCR kit that uses fast amplification protocol and hence has a processing time of 90 minutes. And can process 90 samples per batch per machine. The kit can be used in existing qPCR instruments. It is approved by ICMR with 100 per cent sensitivity and 100 per cent specificity.
Tata we’re promoting two solutions.
One was just a test to be used in any machine. The second was a solution of the tests and the express pcr analyser.
https://tatamd.com/pcr_kits/assets/brochure/RT-PCR-XF_Brochure_21Dec21.pdf
Ok maybe a bit harsh but still. What is on that CV to show he should be running or can run this biz? Nothing I can see. And to be quite frank he approach so far proves he has no clue. His responsibility is to his shareholders. And quite clearly he (so far) is running it like it’s a private business and he is answerable to none. Well he is. I am a large shareholder. He is answerable to me, you and everyone else. And the next time Mandy or anyone emails me on an evening looking for a vote I will let them know where they can shove that request.
CEOs like him get away with being silent as it’s a retail holder base who he knows are fragmented and can’t organise. If he had several big instititions combined do you think his “I do t give a **** I’m DA and I’ll do what I want” approach would wash? They would string him up and send him packing.
Honestly look at his linkedin. He is a journey man. Hops from job to job after a year or so.
I don’t get the initial hype. I can’t see that he has achieved **** all apart from convincing new companies to hire hime every year or 2.
Hey Karen. Have said a few times that novas biggest issue is footprint. The company is probably better off being owned by someone with a much bigger existing global distribution and sales newtwork. The reality is that nova has the tech, the know-how and the products but we are absolutely nowhere (in relative terms) to selling them across the earth. It would take many many years and many many hundreds of millions to build that out. In reality it’s never going to happen. However, someone (like tata) has that in place and they have a brand that opens doors across the most populous and needy (in terms of not just diagnostics but near patient diagnostics) emerging markets.
As such I agree with you, if they start to get traction with their express pcr analyser (our q32) for covid then they will have an established installed based to sell non Covid products in the future. Emerging markets will be the poster child for near poster and portable diagnostics in the future. So much can be done. And as such, Novacyt would be a free option for tata. Buy all their IP, all their tech and know how and take it to India where they have a policy to develop indigenous biotech over foreign imports.
Of course, if that happened there should be HUGe questions asked if this government and the dhsc who appear to have set up the U.K. industry to fail and made them sitting ducks to foreigner takeovers - effectively stealing all their IP through cheap acquisition.
Don’t agree with this. It’s just wild speculation. One of the first contracts we announced in 2020 was in India and we have distribution partners there.
The reason India is a tough market is because in India there is a HUGE biotech industry and they have loads and loads of home grown Novacyts making pcr and LFT tests. You can see the approved and validated lists on the icmr site below. Check it out. Loads of locally made tests and diagnostics companies.
https://www.icmr.gov.in/ckitevaluation.html
For example…. Genetix is our main distributor in India
You recognise the palmQ pro and palmQ mini? Yes that’s right. It’s a q16 and a Q32.
http://genetixbiotech.com/
http://genetixbiotech.com/product/palmq-pro/
http://genetixbiotech.com/product/palmq-mini/
That’s not true. The mygo and own branded machines have been around from before Novacyt purchased IT-IS. And they have actually been available via our Indian distributor since the pandemic started
They have to comply with the listing rules of all and any markets they are listed in individually.
Selling some machines (potentially) to tata would probably not need an RNS unless it was something that would lead to a material change in the markets understanding of the business which they have communicated publicly .